Suchergebnisse - "van de Donk, Niels W C J"

PubPharm (17)

1

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA) : an open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Moreau, P. | Hulin, C. | Perrot, A. | +49

CommentIn: Nat Rev Clin Oncol. 2021 Nov;18(11):676. - PMID 34545220

2

Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study

enthalten in: Haematologica | 2021

von Hulin, C. | Offner, F. | Moreau, P. | +20

3

Sequencing multiple myeloma therapies with and after antibody therapies

enthalten in: Hematology. American Society of Hematology. Education Program | 2020

von van de Donk, N.

4

Should all newly diagnosed MM patients receive CD38 antibody-based treatment?

enthalten in: Hematology. American Society of Hematology. Education Program | 2020

von Korst, C. | van de Donk, N.

5

Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial

enthalten in: Haematologica | 2020

von Zweegman, S. | Stege, C. | Haukas, E. | +23

6

Immunomodulatory effects of CD38-targeting antibodies

enthalten in: Immunology letters | 2018

von van de Donk, N.

ReprintIn: Immunol Lett. 2019 Jan;205:71-77. - PMID 30826127

7

Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment : Results From a Phase II Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2018

von Dimopoulos, M. | Weisel, K. | van de Donk, N. | +15

CommentIn: J Clin Oncol. 2018 Jul 10;36(20):2101-2104. - PMID 29715055

8

Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2017

von Krejcik, J. | Frerichs, K. | Nijhof, I. | +15

9

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

enthalten in: Blood | 2016

von Nijhof, I. | Franssen, L. | Levin, M. | +20

10

Treatment of multiple myeloma with high-risk cytogenetics : a consensus of the International Myeloma Working Group

enthalten in: Blood | 2016

von Sonneveld, P. | Avet-Loiseau, H. | Lonial, S. | +18